Latanoprost Actavis (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye’s ciliary body, which remodels extracellular matrix and enhances uveoscleral outflow of aqueous humor. This increased drainage lowers intra‑ocular pressure, addressing the underlying cause of glaucoma.

The dosing regimen for Latanoprost Actavis is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and schedule must follow the prescriber’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so it should only be used if the potential benefit justifies the potential risk. Breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blocker drops, it often provides greater pressure reduction with fewer systemic side effects, though individual response can vary.

Latanoprost Actavis should be stored at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from light and moisture, and avoid freezing. Do not refrigerate unless otherwise directed by the manufacturer.

Latanoprost Actavis is an ophthalmic solution applied as a single drop into the affected eye(s) once daily, preferably in the evening. Patients should wash their hands, avoid touching the tip of the bottle, and wait a few minutes before applying other eye medications.

Serious but rare risks include severe allergic reactions such as conjunctivitis, corneal edema, macular edema, and vision loss. Any sudden change in vision, eye pain, or severe redness should prompt immediate medical evaluation.

Latanoprost should not be used in patients with active ocular infection or inflammation, hypersensitivity to prostaglandin analogs, or in individuals where the prescriber determines the risks outweigh the benefits. Consultation with an eye care professional is essential before initiating therapy.